Table 1.

Baseline characteristics of patients

Treatment
IFNTemsirolimus
CharacteristicN = 207N = 209
Median age (range), y60 (23–86)58 (32–81)
Age ≥ 65 y65 (31)64 (31)
Sex male148 (72)139 (67)
Karnofsky performance score ≤ 70171 (83)168 (80)
Prior nephrectomy139 (67)139 (66)
Histologic type clear cell170 (82)169 (81)
Lactate dehydrogenase level > 1.5 times upper limit of normal48 (23)36 (17)
Hemoglobin level < lower limit of normal168 (81)172 (82)
Corrected serum calcium level > 2.5mmol/L (10 mg/dL)72 (35)54 (26)
Time from initial diagnosis to randomization < 1 y164 (79)174 (83)
≥2 sites of organ metastasis165 (80)166 (79)
Median baseline cholesterol concentration (range), mmol/La4.2 (1.5–10.4)4.4 (1.0–7.5)
Median baseline triglyceride concentration (range), mmol/La1.4 (0.4–4.5)1.3 (0.4–4.3)
Median baseline glucose concentration (range), mmol/La5.6 (3.1–19.8)5.4 (3.0–14.6)
Treatment with statins at baseline17 (8)17 (8)
Treatment with fibrates at baseline1 (0.5)0 (0)
Treatment with hypoglycemic agents at baseline20 (10)19 (9)
Treatment with statins during study2 (1)23 (11)
Treatment with fibrates during study4 (2)12 (6)
Treatment with hypoglycemic agents during study1 (0.5)26 (12)

NOTE: Values are number (%) unless otherwise labeled.

  • aCholesterol values must be multiplied by 39 to convert from mmol/L to mg/dL, triglyceride values must be multiplied by 89 to convert from mmol/L to mg/dL, and glucose values must be multiplied by 18 to convert from mmol/L to mg/dL.